183 related articles for article (PubMed ID: 27365379)
1. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
[TBL] [Abstract][Full Text] [Related]
2. Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines.
Dagdemir A; Durif J; Ngollo M; Bignon YJ; Bernard-Gallon D
Epigenomics; 2013 Feb; 5(1):51-63. PubMed ID: 23414320
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
4. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Hayden A; Johnson PW; Packham G; Crabb SJ
Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
[TBL] [Abstract][Full Text] [Related]
5. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
Baldan F; Mio C; Lavarone E; Di Loreto C; Puglisi F; Damante G; Puppin C
Oncol Rep; 2015 May; 33(5):2199-206. PubMed ID: 25812606
[TBL] [Abstract][Full Text] [Related]
7. 3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell line.
Hatta M; Naganuma K; Kato K; Yamazaki J
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):269-73. PubMed ID: 26505792
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
Shi Y; Jia Y; Zhao W; Zhou L; Xie X; Tong Z
Int J Mol Med; 2018 Jul; 42(1):435-442. PubMed ID: 29620153
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
[TBL] [Abstract][Full Text] [Related]
13. Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
Chiaradonna F; Barozzi I; Miccolo C; Bucci G; Palorini R; Fornasari L; Botrugno OA; Pruneri G; Masullo M; Passafaro A; Galimberti VE; Fantin VR; Richon VM; Pece S; Viale G; Di Fiore PP; Draetta G; Pelicci PG; Minucci S; Chiocca S
Antioxid Redox Signal; 2015 Jul; 23(1):15-29. PubMed ID: 25897982
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Cheng HT; Hung WC
Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21
Chatterjee B; Ghosh K; Kanade SR
Biofactors; 2019 Sep; 45(5):818-829. PubMed ID: 31317586
[TBL] [Abstract][Full Text] [Related]
16. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.
Bellarosa D; Bressan A; Bigioni M; Parlani M; Maggi CA; Binaschi M
Int J Oncol; 2012 Oct; 41(4):1486-94. PubMed ID: 22797667
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
18. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
19. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
To SQ; Takagi K; Miki Y; Suzuki K; Abe E; Yang Y; Sasano H; Simpson ER; Knower KC; Clyne CD
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):331-8. PubMed ID: 22929011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
